Acceder

Publicaciones - FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA

Cargando...
Solana-Altabella A, Iniesta-Navalon C, Chovi-Trull M, Rodriguez-Veiga R, Lopez-Nogueroles M, Martinez-Cuadron D, Gil-Candel M, Torres-Minana L, Acuna-Cruz E, Cano-Ferri I, Boluda B, Navarro-Vicente I, Lloret-Madrid P, Barragan E, Gil JV, Rodenas-Rovira M, Megias-Vericat JE, Labrador J, Peris-Ribera JE, Poveda-Andres JL, Montesinos P. Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia. Eur J Clin Pharmacol. 2025 Aug 30. doi: 10.1007/s00228-025-03909-4. Online ahead of print. PubMed PMID: 40884550.
AÑO: 2025; IF: 2.4
40884550
Ortiz-Fernandez P, Iniesta-Navalon C, Urbieta-Sanz E, Gascon-Canovas JJ. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases. Clin Rheumatol. 2025 Aug;44(8):3389-3390. doi: 10.1007/s10067-025-07559-w. Epub 2025 Jul 4. No abstract available. PubMed PMID: 40613968.
AÑO: 2025; IF: 2.9
40613968
Iniesta-Navalon C, Rios-Saorin M, Anez-Castano R, Rentero-Redondo L, Ortiz-Fernandez P, Marin-Armero Martinez E, Urbieta-Sanz E. Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab. Ther Drug Monit. 2025 Jun 1;47(3):346-352. doi: 10.1097/FTD.0000000000001269. Epub 2024 Nov 15. PubMed PMID: 40341590.
AÑO: 2025; IF: 2.8
40341590
Ortiz-Fernandez P, Iniesta-Navalon C, Urbieta-Sanz E, Gascon-Canovas JJ. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab". Clin Rheumatol. 2025 Jan 18. doi: 10.1007/s10067-025-07307-0. Online ahead of print. PubMed PMID: 39826047.
AÑO: 2025; IF: 2.9
39826047
Iniesta-Navalon C, Saorin MR, Neira-Torrecillas JM, Rentero-Redondo L, Garcia-Masegosa I, Gil-Almela J, Urbieta-Sanz E. External Evaluation of Population Pharmacokinetic Models of Ustekinumab in Patients with Inflammatory Bowel Disease. Ther Drug Monit. 2025 Apr 3. doi: 10.1097/FTD.0000000000001329. Online ahead of print. PubMed PMID: 40178486.
AÑO: 2025; IF: 2.8
40178486
Siguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA